atom contributes to the antiviral activity of L-3'-Fd4CTP against rtM204V HBV polymerase by readily compensating for the loss of the van der Waals interaction around the 2',3'-double bond through a formation of a hydrogen bond to the amide backbone of rtD205.
Hepatitis B virus (HBV) is the leading cause of chronic hepatitis worldwide. Despite the availability of safe and effective vaccines, the prevalence of HBV-related infection and development of hepatocellular carcinoma have not significantly declined in endemic areas. Thus, treatment with antiviral agents remains the only option available today. Along with the recently approved adefovir dipivoxil (ADV) (Ono-Nita et al., 1999; Perrillo et al., 2000) , alpha interferon (IFN) and lamivudine (3TC) have been used for the treatment of chronic hepatitis B in most countries. Unfortunately, the rate of response to IFN is low, and drugassociated side effects are significant (Hoofnagle et al., 1997; Wong et al., 1993) . Clinicians can now choose to treat with 3TC, a well-tolerated and orally effective drug with minimal side effects (Wang et al., 1998) . As with IFN, however, a complete antiviral response, as assessed by HBe seroconversion, is seen in only a minority of patients after 1 year of treatment (Lai et al., 1998) . Of fundamental concern is that, while initial treatment of patients with 3TC results in a rapid lowering of blood HBV DNA levels, its efficacy is compromised in most patients by the development of drug resistance after prolonged therapy. 3TC resistance has been reported in around 15-25% of patients after 12 months of treatment, increasing with treatment duration (Lai et al., 1998; Dienstag et al., 1999; Liaw et al., 2000) , which is usually associated with mutations in the HBV DNA polymerase gene (Delaney et al., 2001) . The development of resistance is caused by the high rate of virus replication and the error rate of the viral polymerase. One of the common mutations associated with 3TC resistance results in a methionine-to-isoleucine substitution (rtM204I) in the YMDD nucleotide-binding motif in the catalytic domain of the polymerase. Substitution with valine (rtM204V) has been also described, almost invariably in conjunction with an upstream leucine-to-methionine (rtL180M) change in the polymerase B domain Allen et al., 1998; Bartholomew et al., 1997; Seta et al., 2000; Tipples et al., 1996; Yeh et al., 2000) . The
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Comparison of the active sites of the human HIV-1 reverse transcriptase (RT) and the homologymodelled hepatitis B virus (HBV) polymerase
shows that the active sites of both enzymes are open to L-nucleosides, but the position where the 3'-substituent of the L-ribose projects in HBV polymerase is wider and deeper than HIV-1 RT, which enables the HBV polymerase to accommodate various 3'-substituted L-nucleosides. However, the space is not sufficient to accommodate a bulky 3'-substituent such as the 3'-azido group of L-3'-azido-3'-deoxythymidine. Analysis of the minimized structure of rtM204V HBV polymerase/ 3TCTP complex shows that, instead of the steric stress produced by rtV204, a loss of the van der Waals contact around the oxathiolane sugar moiety of 3TCTP caused by the mutation results in the disruption of the active site. Therefore, nucleosides, which are stabilized by additional specific interaction with the enzyme residues, can have more opportunities to circumvent the destabilization by the loss of hydrophobic interaction conferred by mutation. Specifically, the substitution at the 3'-position would be beneficial as the HBV polymerase has wide open space composed of the highly conserved motif (YMDD) where the 3'-substituents of the L-nucleosides project. As an example, our study shows that the 3'-fluorine Introduction emergence of HBV drug resistance highlights the need for the development of alternative therapies that suppress HBV replication in vivo more effectively. For example, a more potent antiviral agent should suppress HBV replication and thus slow the emergence of drug-resistant variants. In view of the fact that a vast number of patients are currently using 3TC, therapies that can also suppress the replication of 3TC-resistant HBV are critically needed. In this regard, the unnatural L-nucleosides attract special attention because they have proven their specific antiviral activities against HBV (Graciet et al., 1999; Gumina et al., 2001b) , which includes L-dT (Afdhal et al., 2002) , L-Fd4C (Lai et al., 2001) and CLV (clevudine) (Chu et al., 1995) . Furthermore, a certain nucleoside such as L-3′-fluoro-2′,3′unsaturated cytidine (L-3′Fd4C), shows antiviral activity against 3TC-resistant HBV polymerase [Stuyver et al. (2003) Potent anti-HBV nucleoside analogs with activity against lamivudine-resistant viruses, 11th International Symposium on Viral Hepatitis & Liver Disease]. As L-nucleosides do not generally show antiviral activity against 3TC-resistant HIV-1 reverse transcriptase (RT) , the structural difference between the HBV polymerase and HIV-1 RT is of interest to investigators. For this purpose, the active site of the homology-modelled three-dimensional structure of the HBV polymerase (Das et al., 2001; was compared with that of HIV-1 RT.
Materials and methods
All molecular modelling of the enzyme-substrate complexes was carried out using Sybyl 6.6 (Tripos, Inc., St Louis, Mo., USA). A three-dimensional homology model of the catalytic core of HBV polymerase was constructed via extrapolation from HIV-1 RT structures (Das et al., 2001; .
Homology modelling of the HBV polymerase
The crystal structure of the covalently trapped catalytic complex of HIV-1 RT with TTP and primer-template duplex (PDB entry 1rtd) (Huang et al., 1998) was used as a template to generate the three-dimensional structure of the HBV polymerase (composer module in Sybyl 6.7) (Das et al., 2001; . The two Mg 2+ ions, thymidine triphosphate and template-primer duplex were located at the same position as the HIV-1 RT DNA dNTP complex structure (1RTD) (Huang et al., 1998) . The stability of the modelled HBV polymerase DNA thymidine triphosphate complex was confirmed by performing molecular mechanics energy minimization and molecular dynamics simulation by using the molecular graphics and simulation program MacroModel, version 7.0 (Schrödinger, Inc., Portland, Oreg., USA) . The complex was minimized until there was no significant movement in atomic coordinates using MMFF94s force field in the presence of GB/SA continuum water model before performing molecular dynamics simulations. A conjugate gradient, Polak-Ribiere first derivative method, was used for energy minimization. Molecular dynamics simulations on HBV polymerase DNA TTP was performed with MMFF94s in the presence of GB/SA continuum water model on a Silicon Graphics Octane2 workstation running the IRIX 6.5 operating system by heating from 0 to 300 K over 5 ps and equilibrating at 300 K for an additional 10 ps. Production dynamics simulations were carried out for 500 ps with a step size of 1.5 fs at 300 K. A shake algorithm was used to constrain covalent bonds to hydrogen atoms. After molecular dynamics simulation, the HBV polymerase DNA TTP ternary complex was fully minimized until there was no significant movement in atomic coordinates (MMFF94s force field, GB/SA water, conjugate gradient and Polak-Ribiere first derivative method) to give the final three-dimensional structure of the HBV polymerase complexed with the DNA duplex and the natural substrate, TTP .
3TC-resistant HIV-1 RT and HBV polymerase
The crystal structure of the covalently trapped catalytic complex of HIV-1 RT with TTP and primer-template duplex (PDB entry 1rtd) (Huang et al., 1998) was used as a template to generate the three-dimensional structure of the M184V RT. The residue rtM184 was mutated to rtV184 in the biopolymer module in Sybyl 6.7. Hydrogen atoms were added to the mutated residue and the side chain was fixed. Gästeiger-Hückel charge (Gästeiger & Marsili, 1980 , Purcell & Singer, 1967 and Kollman-All-Atom charge (Blaney et al., 1982 , Wipff et al., 1983 were loaded to the TTP and rtM184V RT, respectively, and the residues inside 6 Å from TTP were annealed until energy change from one iteration to the next was less than 0.05 kcal/mol . The annealed rtM184V RT-TTP complex was fully minimized by using the Kollman-All-Atom force filed until the iteration number reached 5000. In HBV polymerase, the residue 204 was mutated from methionine to isoleucine, and the same treatment was done to generate the 3TC-resistant rtM204I mutant enzyme.
Nucleoside reverse transcriptase inhibitors
The initial Cartesian coordinates for each inhibitor were generated based on the X-ray coordinates of 3′-azido-3′deoxythymidine (AZT) (Birnbaum et al., 1987) and 2'-3'dideoxycytidine (ddC) (Birnbaum et al., 1988) or conformational analysis (Lee & Chu, 2001) of the modified crystal structures of FTC (Van roey et al., 1993a) and d4C (Van roey et al., 1993b) . The heterocyclic base was appropriately modified before docking into the enzyme. Also, the heterocyclic moiety of n+1th nucleotide in template overhang was modified to the base complementary to the incoming nucleoside RT inhibitor (NRTI) .
Method
Gästeiger-Hückel charge (Gästeiger & Marsili, 1980; Purcell & Singer, 1967) was given to the enzyme-ligand complex with formal charges (+2) to two Mg atoms in the active site. Then, Kollman-All-Atom charges (Blaney et al., 1982; Wipff et al., 1983) were loaded to enzyme site from the biopolymer option in SYBYL 6.6 (Tripos, Inc., St Louis, Mo., USA). Fluorine parameters were obtained from the literature (Cornell et al., 1995; Dunitz & Taylor, 1997) and MM2. In order to eliminate local strains resulting from merging inhibitors and/or point mutations, & Faulds, 1999; † Faraj et al., 1997; ‡ Lin et al., 1994; § Lin et al., 1996; ¶ EC 90 ; ƒChu et al., 1995;  ≠ Relative binding energy =binding energy of nucleoside reverse transcriptase inhibitor triphosphate to reverse transcriptase (RT). Binding energy of dNTP to RT.
residues inside 6 Å from the merged inhibitors and mutated residues were annealed until energy change from one iteration to the next was less than 0.05 kcal/mol (hot region: 6 Å, interesting region: 12 Å). The annealed enzyme-inhibitor complexes were minimized by using Kollman-All-Atom Force Field (Weiner et al., 1986) until the iteration number reached 5000. The binding affinities of the examined structures toward HIV-1 RT and HBV polymerase was estimated by means of the relative binding energy (Erel , Table 1 ) between the inhibitor triphosphate-RT complex and the corresponding natural substrate (dGTP, TTP or dCTP)-RT complex in the energy-minimized states (Lee & Chu, 2001; .
Results

HIV-1 RT vs HBV polymerase
In order for L-nucleosides to be active against HIV-1 RT, the L-ribose moiety should bind to the enzyme active site with an opposite orientation with respect to the D-enantiomer (Lee & Chu, 2001) . The three-dimensional structure of the catalytically competent HIV-1 RT shows an open space at the active site wide enough to accommodate an Lconfigured sugar moiety (Figure 1b) . The homology-modelled active site of HBV polymerase complexed with 3TCTP also shows that its active site is open to L-nucleosides, particularly the position where the 3′-substituent of the L-ribose projects is wider and deeper than RT (Figure 1a ) (Das et al., 2001; . However, the space is not sufficient to accommodate a bulky 3′-substituent such as the 3′-azido group of L-AZT (Figure 2 ). Therefore, even though a number of L-configured nucleoside triphosphates, including L-ddC (Lin et al., 1994) , CLV (Chu et al., 1995) and L-dT (Bryant et al., 2001) show favourable binding affinities to the wild type HBV polymerase, L-AZT (Faraj et al., 1997) does not fit in the active site of HBV polymerase (Table 1) .
rtM184V HIV-1 RT vs rtM204V HBV polymerase
Unlike HIV-1 RT, the bulky side chain of the mutated rtV204 in the rtM204V HBV polymerase/3TC triphosphate complex is not in close proximity to the oxathiolane sugar moiety of 3TC triphosphate to cause the unfavourable steric hindrance. However, the calculated relative binding energy of the rtM204V HBV polymerase/ 3TCTP complex is very low, which indicates that the mutation results in the deformation of the enzyme/ligand complex ( Table 2 ). The mutant enzyme/3TCTP complex has markedly low electrostatic energy. Analysis of the minimized mutant structure in comparison to the wild-type shows a large movement of the 3TCTP toward rtV204, which accompanies a concurrent disruption of the coordination geometry of the two Mg atoms (Figure 3) . The unfavourable close contact (1.5 Å) between two negatively charged aspartic acid residues (rtD83 and rtD205) results in repulsive electrostatic interaction and thereby poor binding energy (Figure 3a ). As the rtM204V mutation reduces the stabilization of the oxathiolane moiety of 3TCTP through the van der Waals interaction, the movement of 3TCTP toward its closest residue rtV204 is conceivable, which results in the disruption of the active site conformation. Therefore, unproductive van der Waals contact in rtM204V HBV polymerase leaves highly unfavourable environment for 3TCTP to bind at the active site.
The binding mode of L-3′-Fd4CTP to the active site of rtM204V HBV polymerase (Figure 4a) shows another example in which the mutated rtV204 does not interfere with the binding of the L-nucleoside triphosphate by the projection of the bulky side chain of valine into the active site of the polymerase. Rather, it is obvious that the direct effect of the mutation is the loss of the stabilizing van der Waals contact not the steric hindrance. However, in this case, the 3′-fluorine atom attached to the 2′,3′-double bond easily compensates for the slight loss of the van der Waals contact by forming a hydrogen bond with the amide backbone of the active site residue, D205 (Figure 4a *Stuyver et al., 2003. polymerase complexed with L-3′-Fd4CTP was much higher than the wild type enzyme complex (Table 2) . Particularly, the electrostatic energy showed large difference between the mutant and the wild type enzyme complexes, which indicates the contribution of the newly formed hydrogen bond to the total binding energy of the nucleoside triphosphate.
Discussion
HBV's genome (approximately 3200 nucleotides) is small and composed of circular, partially double-stranded DNA (Miller et al., 1989) . The viral genome is very compact and contains four overlapping open-reading frames (ORFs) in the negative strand (Tiollais et al., 1985) , among which ORF P covers 75% of the viral genome and encodes for the viral DNA polymerase/RT. The inhibition of HBV Y Chong et al.
Figure 6. 3TCTP complexed with HIV-1 reverse transcriptase and HBV polymerase
In HIV-1 reverse transcriptase (RT) (b and d), the residue rtM184 is located inside a narrow pocket composed of rtQ161, rtY115, rtP157 and rtY183. Therefore, rtM184 has a linear conformation along the pocket. Hepatitis B virus (HBV) polymerase has a much bigger pocket composed of rtA181, rtF88, rtP177 and rtY203 (a and c). Particularly, compared with rtQ161 in RT (b), the short side chain of rtA181 (a) broadens the pocket. As a result, rtM204 in HBV polymerase can adopt a flexible conformation that can wrap around the sugar moiety of 3TCTP by extensive van der Waals interaction. replication by nucleoside analogues results from the recognition of their triphosphates by the RNA-and/or DNA-dependent DNA polymerase of HBV. The product of ORF P is similar to HIV-1 RT in that it has both RT and RNase H activities. Amino acid sequence alignment of the hepadnaviruses P proteins with those of the retroviruses indicates a significant homology within the functional domains, for example, the YMDD motif within the catalytic site of reverse transcriptase. Considering the similarities between HIV-1 RT and HBV polymerase, it is not surprising that many compounds showing anti-HIV activity are also effective against HBV. However, in spite of the lack of the three-dimensional structural information of the HBV polymerase, at least two studies (Maga et al., 1999; Bryant et al., 2000) provide interesting evidence that the active site of the HBV polymerase has an arrangement of its amino acid residues to accommodate wide variety of the unnatural L-nucleoside triphosphates. From the kinetic analysis of the incorporation of D-and L-β-dCTP, β-ddCTP and β-ddFCTP catalysed by HIV-1 RT, Maga and coworkers suggested that the hydroxyl group at the 3′-position of the L-sugar moiety makes an unfavourable steric hindrance with residues in the RT nucleotide binding site, since the affinity increases from the L-2′-deoxy-to the L-2′,3′-dideoxynucleoside triphosphate analogues for HIV-1 RT (Maga et al., 1999) . On the other hand, through an extensive structure-activity analysis, the 3′-OH group of the β-L-2′-deoxynucleoside series was suggested to confer unique specificity for anti-HBV activity (Bryant et al., 2001) . From these studies, it is clear that the active site of the HBV polymerase has an open space wide enough to accommodate the 3′-substituted β-L-2′-deoxynucleoside.
The high anti-HBV activity of two β-L-2′-deoxynucleosides which have 3′-OH groups of CLV and L-dT (Bryant et al., 2000) , strongly supports this idea. Modelled the active site of HBV polymerase complexed with 3TCTP also demonstrates that there is enough space at the 3′-position of the L-nucleoside (Figure 1a ). However, it is interesting to note that the active site of HBV polymerase is not wide enough to accommodate a bulky 3′-substituent such as the 3′-azido group of L-AZT ( Figure 2 ) (Faraj et al., 1997) , which shows no antiviral activity against HBV. Related to the structural difference between the active sites of HIV-1 RT and HBV polymerase, of greater interest is the mechanism of 3TC-resistance. The computergenerated, energy-minimized model of HIV-1 RT complexed with 3TCTP clearly shows that the 3TCTP and TTP configurations are enantiomeric, so that alignment of the triphosphates and bases would cause the nucleoside ring of the β-L-inhibitor such as 3TC to project 1.5-2.0 Å further toward residue 184 than would the carbohydrate moiety of TTP ( Figure 5) . As a result, in WT RT, rtM184 and the β-L-oxathiolane moiety of 3TC are in a very stable extended van der Waals contact. However, in 3TC-resistant mutant HIV-1 RT (rtM184V), the Cγ2 methyl group of rtV184 and the protruding β-L-oxathiolane ring would be in an unfavourably close contact (1.8 Å in rtM184V vs. 3.3 Å in wild-type), which would result in severe steric hindrance ( Figure 5 ). In this context, it is noteworthy that, L-configured nucleosides hardly show antiviral activity against the M184V RT. In view of the structural similarity between HIV-1 RT and HBV polymerase, Das et al. also suggested that the steric hindrance between the mutant amino acid side chain and 3TC could account for the resistance phenotype (Das et al., 2001) . Specifically, steric conflict between the Cγ2-methyl group of Ile or Val at position 204 in HBV polymerase and the sulphur atom in the oxathiolane ring is proposed to account for the resistance observed upon rtM204I/V mutation (Das et al., 2001) . Therefore, according to this mechanism, as noted with rtM184V HIV-1 RT, it is not favourable for L-configured nucleosides to bind to the mutant HBV polymerase of which rtM204 is mutated to the sterically demanding isoleucine or valine. However, the moderate to potent antiviral activities of several L-nucleosides such as L-dT (Afdhal et al., 2002) , L-d4FC (Lai et al., 2001) , CLV (Chu et al., 1995) and L-3′-Fd4C (Gumina et al., 2001a; Stuyver et al., 2002) against rtM204V HBV polymerase do not allow this generalization. In order to address this challenging question, computer-generated rtM184V HIV-1 RT and rtM204V HBV polymerase complexed with a DNA duplex as well as a natural substrate (TTP) were energyminimized under the same conditions. In HIV-1 RT, the residue rtM184 is located inside a narrow pocket composed of rtQ161, rtY115, rtP157 and rtY183 (Figure 6b ). Therefore, rtM184 has a linear conformation along the pocket (Figure 6b,d) . However, HBV polymerase has a much bigger pocket composed of rtA181, rtF88, rtP177 and rtY203 (Figure 6a,c) . Particularly, in comparison to rtQ161 in RT, the short side chain of rtA181 in HBV polymerase broadens the pocket. As a result, rtMt204 in HBV polymerase can adopt a flexible conformation which can wrap around the sugar moiety of 3TCTP by the extensive van der Waals interaction (Figure 3b ). Upon mutation to valine, the narrow pocket where rtM184 resides in HIV-1 RT strongly limits the conformation of the side chain of rtV184. Under the given circumstances, projection of the side chain into the nucleoside binding site, which does not allow binding of L-nucleoside triphosphate, is the lowest energy conformation of rtV184 (Figure 7b ). However, by virtue of the loose environment around the residue 204, the bulky side chain of rtV204 of rtM204V HBV polymerase can stay away from the nucleoside binding site to avoid the unfavourable steric hindrance with the incoming L-nucleoside triphosphate (Figure 7a) . Additionally, the bulky side chain of rtL180 in HBV polymerase prevents the rotation of the side chain of rtV204 into the active site ( Figure 7c ). Therefore, it is unlikely that the 3TC-resistance in rtM204V HBV polymerase happens in the similar way as in HIV-1 RT. Our molecular modelling study of rtM204V HBV polymerase/3TCTP complex shows that, instead of imposing steric pressure into the nucleoside binding site, the mutation from methionine to valine followed by the loss of van der Waals interaction is believed to destabilize the enzyme/3TCTP complex. Not unexpectedly, in the relatively wide active site of HBV polymerase (the closest enzyme residue from 3TCTP is rtM204, which is 3.5Å away), the nonspecific van der Waals interaction between the enzyme residue, particularly rtM204, and the sugar moiety of the L-configured nucleoside triphosphate is critical for stabilizing the enzyme/nucleoside complex. Therefore, nucleosides, which are able to specifically interact with enzyme residues, would have benefits in coping with the loss of the nonspecific hydrophobic interaction caused by mutation. Specifically, the substitution at the 3′-position would be more beneficial as the active site of the HBV polymerase has an open space composed of the highly conserved secondary structure (YMDD motif ) where the 3′-substituents of the L-nucleosides project. As an example, in rtM204V HBV polymerase/L-3′Fd4CTP complex (Figure 4) , the mutation also results in the loss of the van der Waals contact between rtM204 and the 2′,3′double bond of the sugar moiety. However, a slight movement of the nucleoside triphosphate toward rtV204 followed by a formation of the hydrogen bonding between the 3′-F atom and amide backbone of rtD205 can readily compensate for the loss of van der Waals contact.
In summary, the comparison of the active sites of the HIV-1 RT and the homology-modelled HBV polymerase shows that the active sites of both enzymes are open to L-nucleosides, but the position where the 3′-substituent of the L-ribose projects in HBV polymerase is wider and deeper than RT, which enables the HBV polymerase to accommodate various 3′-substituted L-nucleosides. Thus, it is unlikely that the two enzymes have the same mechanism of 3TC-resistance. The analysis of the minimized structure of rtM204V HBV polymerase/3TCTP complex shows that a loss of the van der Waals contact around the oxathiolane sugar moiety of 3TCTP results in the disruption of the active site. Therefore, upon mutation, nucleosides which can be stabilized by the additional specific interaction with enzyme residues, may be able to circumvent the destabilization caused by the loss of the hydrophobic interaction. Specifically, the substitution at the 3′-position would be beneficial as the active site of the HBV polymerase has an open binding site composed of the highly conserved motif (YMDD) where the 3′-substituents of the L-nucleosides project. As an example, our study shows that the 3′-fluorine atom contributes for the antiviral activity of L-3′-Fd4CTP against rtM204 HBV polymerase by readily compensating for the loss of the van der Waals interaction around the 2′,3′-double bond through a formation of a hydrogen bond. Thus, within the limitations of the homology modelling of the HBV polymerase by using the crystal structure of the HIV-1 reverse transcriptase as a template, this work provides a rationale for developing additional nucleosides modified at the 3′-position.
